NICE recommends Revlimid as multiple myeloma alternative
The new indication will benefit approximately 2,100 patients.
17th May 2019
Latest news
Rise in bowel cancer numbers among young adults
The researchers retrieved data on 143.7 million people aged 20 to 49 years from 20 European countries.
17th May 2019
Revlimid, Imnovid combos receive EU approval
The approval of these combination therapies “Marks a significant milestone for patients with multiple myeloma in Europe".
17th May 2019
Fragmin approved by FDA as first anticoagulant for children
The drug was initially approved by the FDA in 1994 for adults and is a type of heparin.
17th May 2019
Winners announced - 2019 International Clinical Researcher of the Year!
The winners of the PharmaTimes International Clinical Researcher of the Year have been announced, find out who emerged victorious in the 2019 competition.
17th May 2019
ICR launches ‘Darwinian’ cancer drug programme
The programme is to be launched in a £75 million state-of-the-art global centre of expertise in anti-evolution therapies in London.
16th May 2019
New tech to protect prostate cancer patients during radiation treatment
SpaceOAR hydrogel acts as a spacer, reducing the amount of radiation that can pass through the prostate and damage the rectum during treatment.
16th May 2019
AZ confirms cardiovascular safety with roxadustat results
The companies will begin discussions with the US Food and Drug Administration (FDA) to prepare for regulatory submission.
16th May 2019
Pfizer announces positive dermatitis therapy phase III results
The company's Janus kinase 1 has met all co-primary and secondary endpoints in a pivotal Phase III study.
16th May 2019
Rise in heart and circulatory disease deaths
The worrying rise bucks decades of progress that has seen annual deaths from heart and circulatory disease half since the 1960s.
16th May 2019
NICE recommends Sprinraza for 5q spinal muscular atrophy
The recommendation is for infants, children and adults with 5q spinal muscular atrophy and will be available through a scheme known as a Managed Access Agreement.
15th May 2019
Regeneron’s Eylea wins FDA approval
The drug is the only VEGF inhibitor approved with two dosing options for diabetic retinopathy.
15th May 2019
BMJ publishes subclinical hypothyroidism guideline
The guideline states that thyroid hormones should not be routinely offered to adults with subclinical hypothyroidism.
15th May 2019
FDA approval for Bavencio combo in advanced RCC
The decision was based on positive results from the Phase III JAVELIN Renal 101 study.
15th May 2019
Why agencies and in-house pharma professionals should enter the 2019 Communications Team of the Year competition
Unique in the industry, the PharmaTimes Communications Team of the Year competition gives communications professionals the opportunity to demonstrate their skills in a live environment, developing a strategic and tactical pitch in response to a fictional, but realistic challenge.
15th May 2019
